These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1888251)

  • 1. Symptoms associated with tamoxifen treatment in postmenopausal women.
    Love RR; Cameron L; Connell BL; Leventhal H
    Arch Intern Med; 1991 Sep; 151(9):1842-7. PubMed ID: 1888251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
    Kenemans P; Kubista E; Foidart JM; Yip CH; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Beckmann MW; Bundred NJ; Egberts J; van Os S; Planellas J
    Breast; 2007 Dec; 16 Suppl 2():S182-9. PubMed ID: 17983942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
    Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
    Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tamoxifen in the long-term treatment and prevention of breast cancer.
    Jordan VC
    Oncology (Williston Park); 1988 Sep; 2(9):19-28. PubMed ID: 3079292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
    Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
    Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen therapy in breast cancer control worldwide.
    Love RR; Koroltchouk V
    Bull World Health Organ; 1993; 71(6):795-803. PubMed ID: 8313498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
    Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
    Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.